Optimal timing of thoracic radiotherapy in limited stage small cell lung cancer (SCLC) with daily fractionation: A brief report

Shaakir Hasan; Richard White; Paul Renz; Stephen Abel; Zachary Otaibi; Dulabh Monga; Athanasios Colonias; Rodney E Wegner

doi:10.1016/j.radonc.2018.11.005

Optimal timing of thoracic radiotherapy in limited stage small cell lung cancer (SCLC) with daily fractionation: A brief report

Radiother Oncol. 2019 Mar:132:23-26. doi: 10.1016/j.radonc.2018.11.005. Epub 2018 Dec 20.

Authors

Shaakir Hasan¹, Richard White², Paul Renz³, Stephen Abel⁴, Zachary Otaibi⁵, Dulabh Monga⁵, Athanasios Colonias⁴, Rodney E Wegner⁴

Affiliations

¹ Allegheny Health Network Cancer Institute, Division of Radiation Oncology, Pittsburgh. Electronic address: Shaakir.Hasan@ahn.org.
² Allegheny Health Network, Department of Internal Medicine, Pittsburgh.
³ West Virginia University, Division of Radiation Oncology, Morgantown.
⁴ Allegheny Health Network Cancer Institute, Division of Radiation Oncology, Pittsburgh.
⁵ Allegheny Health Network Cancer Institute, Division of Medical Oncology, Pittsburgh, United States.

Abstract

Survival in limited stage small cell lung cancer (LS-SCLC) improves with faster initiation of hyper-fractionated thoracic radiotherapy (TRT) following chemotherapy, however, it is unknown if this association exists for more commonly employed daily fractionated regimens. Our results suggest that this association is present even with daily fractionation.

Keywords: Lung cancer; Small cell; Thoracic radiation.

MeSH terms

Adult
Aged
Dose Fractionation, Radiation
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Neoplasm Staging
Small Cell Lung Carcinoma / drug therapy
Small Cell Lung Carcinoma / pathology
Small Cell Lung Carcinoma / radiotherapy*

Grants and funding

U54 GM104942/GM/NIGMS NIH HHS/United States